India’s GlaxoSmithKline (GSK) Pharmaceuticals has informed that it has signed a co-promotion agreement with Daiichi Sankyo India Pharma (DSIN) for the antihypertensive drug Olmesartan Medoxomil and its combination products.

DSIN is a subsidiary of Daiichi Sankyo Co., a leading Japanese pharmaceuticals company based in Tokyo. Olmesartan, an original research product of Daiichi Sankyo is a US$ 2 billion worth drug for the company and is available in more than 50 countries worldwide.

GlaxoSmithKline Pharma is a 49 per cent subsidiary of UK drugmaker GlaxoSmithKline Plc. Earlier this month, the company entered into a collaboration with the Japan-based Astellas Pharma Inc. for selling its anti-fungal injectable 'Micafungin' in the Indian market.

Micafungin, an original research product of Astellas, was approved by the FDA in 2005.